Identifying gene expression predictive of response to neoadjuvant endocrine therapy in early breast cancer
These findings suggest that CXCL9 and NPY1R could serve as predictive biomarkers for endocrine therapy response. Identifying these biomarkers may facilitate personalized treatment strategies, including the addition of therapies such as chemotherapy for resistant cases.
Authors
- Aiko Sueta
- Mai Tomiguchi (ORCID: https://orcid.org/0000-0002-1210-2894)
- Lisa Goto‐Yamaguchi
- Yutaka Yamamoto (ORCID: https://orcid.org/0000-0002-4577-1234)
- Kaori Hidaka
Institutions
- Kumamoto University Hospital (JP)
- Uji Hospital (JP)
- Kumamoto University (JP)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1007/s10549-025-07693-8
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Gilead Sciences
- Ministry of Education, Culture, Sports, Science and Technology
- Daiichi-Sankyo
- Kumamoto University
- Ono Pharmaceutical
- Chugai Pharmaceutical
- RIKEN